Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,503 shares of the biopharmaceutical company’s stock after selling 168 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Gilead Sciences were worth $755,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GILD. Allspring Global Investments Holdings LLC raised its stake in Gilead Sciences by 3.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 922,960 shares of the biopharmaceutical company’s stock valued at $67,607,000 after acquiring an additional 35,021 shares during the last quarter. Maryland State Retirement & Pension System raised its stake in Gilead Sciences by 0.9% during the 1st quarter. Maryland State Retirement & Pension System now owns 98,139 shares of the biopharmaceutical company’s stock valued at $6,599,000 after acquiring an additional 832 shares during the last quarter. Diversify Advisory Services LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at approximately $316,000. Mission Wealth Management LP raised its stake in Gilead Sciences by 3.0% during the 1st quarter. Mission Wealth Management LP now owns 12,454 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 368 shares during the last quarter. Finally, Prosperity Consulting Group LLC raised its stake in shares of Gilead Sciences by 1,175.8% during the 1st quarter. Prosperity Consulting Group LLC now owns 52,985 shares of the biopharmaceutical company’s stock worth $3,881,000 after buying an additional 48,832 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock valued at $3,033,340 over the last quarter. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $88.29 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $89.74. The stock has a market cap of $110.00 billion, a price-to-earnings ratio of 245.25, a price-to-earnings-growth ratio of 3.07 and a beta of 0.18. The business has a fifty day moving average of $83.28 and a 200-day moving average of $73.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, analysts predict that Gilead Sciences, Inc. will post 3.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research note on Monday, September 16th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 9th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 target price on shares of Gilead Sciences in a research note on Tuesday. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.